Decoy Wnt receptor sLRP6E1E2 decreases proliferation in human lung cancer cells.

<p>(a) A549 and H322 cells were transduced with dE1-k35/LacZ or dE1-k35/sLRP6E1E2 (20 MOI). The next day, these cells were incubated with or without Wnt3a (100 ng/ml). After 3 days, cell proliferation was assessed by the MTT assay (mean ± SEM). *<i>P</i><0.05, ^#<i>P</i><0.01 versus untreated control for each group; **<i>P</i><0.001 versus dE1-k35/LacZ-transduced or PBS-treated cells. n.s. = not significant. (b) A549 cells were treated as indicated above (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0036520#pone-0036520-g003" target="_blank">Fig. 3a</a>). Western blot using antibodies specific to LRP6, Dvl2, Axin, Cyclin D1, or GSK-3β. (c) A549 cells were harvested at 6 hr after Wnt3a treatment. The p-Erk1/2, Erk1/2, p-PI3K, PI3K, p-Akt, and Akt proteins were detected by western blot analysis.